Inhalant allergen immunotherapy Survey Question Title * 1. What country are you from? Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Terr British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile Christmas Island Cocos (Keeling) Islands Colombia Comoros Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands/Malvinas Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Terr Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea Kosovo Kuwait Kyrgyzstan Lao People's Dem Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peoples Republic of China Peoples Republic of Korea Peru Philippines Pitcairn Poland Portugal Qatar Republic of Congo Reunion Romania Russia Rwanda Saint Barthelemy Saint Helena Saint Kitts and Nevis Saint Lucia Saint Martin Saint Pierre and Miquelon Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the SSI Spain Sri Lanka St Vincent and Grenadines Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay US Minor Outlying Islands US Virgin Islands Uzbekistan Vanuatu Venezuela Viet Nam Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Question Title * 2. Is allergen immunotherapy available in your country? Yes No Question Title * 3. Is allergen immunotherapy funded by your national health system? Yes No Question Title * 4. Where is your practice located? Europe North America South America Central America Australia Asia: Middle East South East Asian Asia Africa Other: Please, state your country: Question Title * 5. What is your primary specialty? Allergology Immunology Allergology and Clinical Immunology Pulmonology Pediatrics Dermatology General Practice/Primary Care Otorhinolaryngology (ENT) Other or secondary specialties (please specify): Question Title * 6. Inhalant IT is used to treat: Allergic rhinoconjunctivitis Allergic asthma Allergic rhinoconjunctivitis as asthma profilaxis A and B All of above None Question Title * 7. Which is the indication you follow for this prescription? Medical management failure Patient´s preference Pharmacoeconomics Asthma appearance prevention First line treatment Other (please specify): Question Title * 8. Which of the following describes your practice type the best? Please select all that apply Academic setting, research field Public health system Private practice Combination of 2, which? All of above Question Title * 9. In which location is the AIT administered? Hospital Outpatient clinic Primary care center Research facilities (Not hospital based) By a doctor or nurse at the patient’s house By the patient in no specific location Other Question Title * 10. In case it is administered in a medical facility, where is AIT administered? Day hospital IT unit No specific room is assigned for it Question Title * 11. What kind of administration route do you prescribe (Please select a percentage in all that apply) Subcutaneous immunotherapy: % Sublingual immunotherapy – tablet: % Sublingual immunotherapy – drops: % Oral immunotherapy: % Epicutaneous immunotherapy: % Intralymphatic: % More than one, including simultaneous combination: % Question Title * 12. Is your patient population mainly: Polysensitized Monosensitized Question Title * 13. How many allergen extracts do you mix in the same immunotherapy vaccine in a polysensitized patient? Only one Two More than two Question Title * 14. Which parameters do you use to guide AIT? Equally high sIgE to 2 or more allergens? Positive skin prick test Clinical history pointing to the causative role of several allergens Positive intranasal challenge to two and more allergens? Other considerations Question Title * 15. In case you use more than one extract in the same vaccine which type do you use? Monocomponent vaccines (e.g. 100% birch and 100% grass) Polivalent vaccines (e.g. 50% birch and 50% grass) Question Title * 16. In case you use more than one extract in the same vaccine which type of mixtures do you use? Just pollens Dust+pollen Dander+dust Dander+pollen Mold+dust Other (please specify): Question Title * 17. What kind of extract do you use? Native allergen Allergoids Both Question Title * 18. Do you use standardized extracts? Always Never Sometimes (State a percentage): Question Title * 19. After how many years do you discontinue immunotherapy? One year Three years Four years Five years More than five years Life-long Other; specify in years Question Title * 20. In case the decision to discontinue AIT is not made only the basis of time which criteria do you use: (more than 1 can be selected) Reduced symptom and medication scores Negative skin prick test Negative intranasal challenge Decrease in sIgE levels Increase in sIgG4 Increased IgE-FAB Product-specific recommendations by the manufacturer Patient’s compliance Question Title * 21. How long do you administer IT throughout the year? Pre-seasonal Pre- and co-seasonal Co-seasonal Perennial Booster Other (please specify) Question Title * 22. What kind of immunotherapy build-up schedule do you use? Conventional Cluster Rush Ultra-rush All of the above Other Question Title * 23. How many patients in your practice are currently undergoing an inhalant allergen immunotherapy? 0%-10% 11%-20% >20% Question Title * 24. Do you use any follow-up tool to promote adherence? Patient reminder Reaching out to no-show patients None Other Complete